Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
WHO's hydroxychloroquine trial suspended pending safety data, Bloomberg says » 18:00
05/25/20
05/25
18:00
05/25/20
18:00
MYL

Mylan

$15.63 /

-0.37 (-2.31%)

, TEVA

Teva

$11.97 /

-0.05 (-0.42%)

, NVS

Novartis

$84.84 /

-0.12 (-0.14%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

The World Health…

The World Health Organization temporarily halted tests on hydroxychloroquine in its COVID-19 drug trials pending more data because of safety concerns, Bloomberg's Corinne Gretler reports. The steering committee decided to suspend enrollment to that arm of the so-called Solidarity trials, WHO officials said Monday. That's after the Lancet published a study that said the drug, touted by U.S. President Donald Trump as a treatment, was linked to an increased risk of death and heart ailments, the author notes. Mylan (MYL), Teva (TEVA), Novartis (NVS), and Bayer (BAYRY) are among companies that had announced efforts to increase hydroxychloroquine production early in the COVID-19 outbreak. Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
TEVA Teva
$11.97 /

-0.05 (-0.42%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
NVS Novartis
$84.84 /

-0.12 (-0.14%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

Saturday
On The Fly
Week in Review: How Trump's policies moved stocks » 09:55
05/23/20
05/23
09:55
05/23/20
09:55
AZN

AstraZeneca

$55.21 /

-0.04 (-0.07%)

, MRNA

Moderna

$69.00 /

+1.99 (+2.97%)

, JNJ

Johnson & Johnson

$144.37 /

-0.29 (-0.20%)

, SNY

Sanofi

$47.31 /

-0.18 (-0.38%)

, MRK

Merck

$76.37 /

-0.17 (-0.22%)

, MYL

Mylan

$15.63 /

-0.37 (-2.31%)

, TEVA

Teva

$11.97 /

-0.05 (-0.42%)

, NVS

Novartis

$84.84 /

-0.12 (-0.14%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, LITE

Lumentum

$73.50 /

+1.74 (+2.42%)

, NPTN

NeoPhotonics

$8.31 /

+ (+0.00%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

NPTN NeoPhotonics
$8.31 /

+ (+0.00%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
05/01/20 Guggenheim
AstraZeneca price target raised to 9,100 GBp from 8,900 GBp at Guggenheim
MRNA Moderna
$69.00 /

+1.99 (+2.97%)

05/20/20 Morgan Stanley
Moderna price target raised to $90 from $37 at Morgan Stanley
05/19/20 Piper Sandler
Piper trims Moderna target to $100 on capital raise dilution
05/19/20 BMO Capital
Moderna price target raised to $112 from $83 at BMO Capital
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
04/28/20 UBS
Johnson & Johnson downgraded to Neutral from Buy at UBS
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
04/28/20 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
MRK Merck
$76.37 /

-0.17 (-0.22%)

05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
MYL Mylan
$15.63 /

-0.37 (-2.31%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
TEVA Teva
$11.97 /

-0.05 (-0.42%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
NVS Novartis
$84.84 /

-0.12 (-0.14%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
LITE Lumentum
$73.50 /

+1.74 (+2.42%)

05/21/20 Rosenblatt
Rosenblatt sees little impact on Lumentum, NeoPhotonics' current sales to Huawei
05/06/20 Craig-Hallum
Lumentum price target raised to $100 from $95 at Craig-Hallum
05/06/20 Piper Sandler
Lumentum price target raised to $100 from $95 at Piper Sandler
05/05/20 Raymond James
Lumentum price target raised to $97 from $90 at Raymond James
NPTN NeoPhotonics
$8.31 /

+ (+0.00%)

05/01/20 Northland
NeoPhotonics price target raised to $13 from $9.75 at Northland
05/01/20 Piper Sandler
NeoPhotonics price target raised to $14 from $9 at Piper Sandler
04/24/20 Rosenblatt
NeoPhotonics downgraded to Neutral at Rosenblatt with stock near three-year high
TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

NPTN NeoPhotonics
$8.31 /

+ (+0.00%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

  • 19
    May
TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

NPTN NeoPhotonics
$8.31 /

+ (+0.00%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

Friday
Periodicals
Hydroxychloroquine linked to higher death risk in COVID patients, WaPo reports » 08:41
05/22/20
05/22
08:41
05/22/20
08:41
MYL

Mylan

$16.00 /

-0.34 (-2.08%)

, TEVA

Teva

$12.02 /

+0.02 (+0.17%)

, NVS

Novartis

$84.96 /

-0.97 (-1.13%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Hydroxychloroquine, the…

Hydroxychloroquine, the anti-malaria drug that President Trump has said that he has been taking to prevent himself from contracting coronavirus infection, has been linked to a significantly higher risk of death and patients taking it were also more likely to develop a type of irregular heart rhythm that can lead to sudden cardiac death, a study published in medical journal the Lancet concluded, reported The Washington Post's Ariana Eunjung Cha and Laurie McGinley. Mylan (MYL), Teva (TEVA), Novartis (NVS), and Bayer (BAYRY) are among companies that had announced efforts to increase hydroxychloroquine production early in the COVID-19 outbreak. Reference Link

ShowHide Related Items >><<
TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
TEVA Teva
$12.02 /

+0.02 (+0.17%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
NVS Novartis
$84.96 /

-0.97 (-1.13%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

Over a week ago
Periodicals
Trump taking hydroxychloroquine to prevent coronavirus infection, CNBC says » 16:56
05/18/20
05/18
16:56
05/18/20
16:56
MYL

Mylan

$16.46 /

+1.3 (+8.58%)

, NVS

Novartis

$84.87 /

+0.89 (+1.06%)

President Trump said …

President Trump said that he has been taking anti-malaria drug hydroxychloroquine fo more than a week to to prevent himself from contracting coronavirus infection, reports CNBC. The Fly notes that Mylan (MYL) and Novartis (NVS) are making chloroquine tablets to fight COVID-19. Reference Link

ShowHide Related Items >><<
NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
NVS Novartis
$84.87 /

+0.89 (+1.06%)

05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
04/29/20 JPMorgan
Novartis price target lowered to CHF 84 from CHF 91 at JPMorgan
NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

On The Fly
Fly Intel: Pre-market Movers » 09:11
05/13/20
05/13
09:11
05/13/20
09:11
GILD

Gilead

$77.94 /

-2.86 (-3.54%)

, ROKU

Roku

$127.14 /

-5.06 (-3.83%)

, JCP

J.C. Penney

$0.20 /

+0.0447 (+29.06%)

, JD

JD.com

$47.03 /

+0.31 (+0.66%)

, LVS

Las Vegas Sands

$45.97 /

-2.51 (-5.18%)

, MYL

Mylan

$16.21 /

-0.7 (-4.14%)

, UNFI

United Natural Foods

$15.54 /

+2.87 (+22.65%)

, CYBR

CyberArk

$109.65 /

-5.33 (-4.64%)

, INFN

Infinera

$5.81 /

+0.17 (+3.01%)

, ADPT

Adaptive Biotechnologies

$38.10 /

-0.03 (-0.08%)

, NE

Noble Corp.

$0.21 /

+0.0035 (+1.74%)

, BLUE

Bluebird Bio

$56.85 /

-3.37 (-5.60%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

INFN Infinera
$5.81 /

+0.17 (+3.01%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

CYBR CyberArk
$109.65 /

-5.33 (-4.64%)

BLUE Bluebird Bio
$56.85 /

-3.37 (-5.60%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

05/11/20 RBC Capital
Gilead's U.S. remdesivir supply to be 'severely constrained', says RBC Capital
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Citi
ICER value of Remdesivir at $4,500 supportive of value, says Citi
05/04/20 Benchmark
Regeneron report more about COVID-19 progress than earnings, says Benchmark
ROKU Roku
$127.14 /

-5.06 (-3.83%)

05/08/20 Susquehanna
Roku price target lowered to $145 from $170 at Susquehanna
05/08/20 Loop Capital
Roku price target raised to $90 from $70 at Loop Capital
05/08/20 Wedbush
Roku price target raised to $136 from $86 at Wedbush
04/29/20
Fly Intel: Top five analyst initiations
JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

04/16/20 Oppenheimer
Ulta Beauty price target raised to $240 from $220 at Oppenheimer
01/14/20 Oppenheimer
Ulta Beauty price target raised to $310 from $275 at Oppenheimer
11/18/19 Deutsche Bank
Deutsche Bank stays on sidelines despite J.C. Penney's margin gains
07/25/19 Oppenheimer
Ulta Beauty price target raised to $390 from $370 at Oppenheimer
JD JD.com
$47.03 /

+0.31 (+0.66%)

05/13/20 Mizuho
JD.com upgraded to Buy from Neutral at Mizuho
04/14/20 Morgan Stanley
JD.com upgraded to Overweight from Equal Weight at Morgan Stanley
03/17/20 Bernstein
JD.com upgraded to Outperform from Market Perform at Bernstein
03/03/20 Susquehanna
JD.com price target raised to $45 from $35 at Susquehanna
LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

05/06/20 Roth Capital
Las Vegas Sands price target lowered to $52 from $69 at Roth Capital
04/23/20
Fly Intel: Top five analyst upgrades
04/23/20 JPMorgan
JPMorgan upgrades Las Vegas Sands to Overweight, sees entry point
04/23/20 Deutsche Bank
Las Vegas Sands price target raised to $54 from $50 at Deutsche Bank
MYL Mylan
$16.21 /

-0.7 (-4.14%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

05/13/20 Wells Fargo
United Natural Foods upgraded to Equal Weight on COVID benefits at Wells Fargo
05/13/20 Wells Fargo
United Natural Foods upgraded to Equal Weight from Underweight at Wells Fargo
03/19/20 Barclays
United Natural Foods upgraded to Equal Weight from Underweight at Barclays
03/18/20 BMO Capital
United Natural Foods upgraded to Market Perform from Underperform at BMO Capital
CYBR CyberArk
$109.65 /

-5.33 (-4.64%)

04/08/20 DA Davidson
DA Davidson says Proofpoint, SailPoint have strongest pipelines in sector
03/24/20 Goldman Sachs
Goldman Sachs starts Rapid7, Tenable Holdings at Buy, SailPoint at Sell
03/24/20 Goldman Sachs
CyberArk initiated with a Neutral at Goldman Sachs
03/23/20 Piper Sandler
CyberArk upgraded to Overweight on recent selloff at Piper Sandler
INFN Infinera
$5.81 /

+0.17 (+3.01%)

05/13/20 Northland
Infinera downgraded to Market Perform with $5 target at Northland
05/13/20 Northland
Infinera downgraded to Market Perform from Outperform at Northland
05/13/20 MKM Partners
Infinera price target lowered to $7.50 from $10.50 at MKM Partners
05/13/20 Northland
Infinera downgraded to Market Perform from Outperform at Northland
ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

05/13/20 Credit Suisse
Noble Corp. downgraded to Underperform from Neutral at Credit Suisse
04/21/20 RBC Capital
Noble Corp. downgraded to Underperform from Sector Perform at RBC Capital
03/17/20 Capital One
Noble Corp. downgraded to Underweight from Equalweight at Capital One
03/13/20 Wells Fargo
Drillers downgraded at Wells Fargo on recent sell off in commodity prices
BLUE Bluebird Bio
$56.85 /

-3.37 (-5.60%)

05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
05/11/20 Piper Sandler
Bluebird Bio price target lowered to $70 from $75 at Piper Sandler
03/27/20 BMO Capital
Bluebird Bio price target lowered to $107 from $132 at BMO Capital
UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

INFN Infinera
$5.81 /

+0.17 (+3.01%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

CYBR CyberArk
$109.65 /

-5.33 (-4.64%)

BLUE Bluebird Bio
$56.85 /

-3.37 (-5.60%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

CYBR CyberArk
$109.65 /

-5.33 (-4.64%)

UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

INFN Infinera
$5.81 /

+0.17 (+3.01%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

Hot Stocks
Mylan to supply investigational antiviral remdesivir for COVID-19 treatment » 16:19
05/12/20
05/12
16:19
05/12/20
16:19
MYL

Mylan

$16.21 /

-0.7 (-4.14%)

, GILD

Gilead

$77.95 /

-2.85 (-3.53%)

Mylan (MYL) announced, as…

Mylan (MYL) announced, as part of its ongoing efforts to support patients and public health needs during the COVID-19 pandemic, a global collaboration with Gilead Sciences (GILD) to expand access to the investigational antiviral remdesivir for the potential treatment of COVID-19. Under the terms of the license agreement signed with Gilead, Mylan has rights to manufacture and distribute remdesivir in 127 low- and middle-income countries, including India. The agreement is non-exclusive, allowing for multiple licensees to ensure extensive access to this treatment, once approved as safe and effective for COVID-19 patients. "To ensure preparedness in this critical time of need, Mylan is confident it will be able to develop a bioequivalent version of remdesivir, including production of its own active pharmaceutical ingredient and the finished dosage form in sterile powder lyophilized vials for administration of the medicine by intravenous infusion. We will be in a position to provide product in the coming months, subject to reviews by national regulatory bodies and the Prequalification Program of the World Health Organization."

ShowHide Related Items >><<
MYL Mylan
$16.21 /

-0.7 (-4.14%)

GILD Gilead
$77.95 /

-2.85 (-3.53%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
GILD Gilead
$77.95 /

-2.85 (-3.53%)

05/11/20 RBC Capital
Gilead's U.S. remdesivir supply to be 'severely constrained', says RBC Capital
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Citi
ICER value of Remdesivir at $4,500 supportive of value, says Citi
05/04/20 Benchmark
Regeneron report more about COVID-19 progress than earnings, says Benchmark
MYL Mylan
$16.21 /

-0.7 (-4.14%)

GILD Gilead
$77.95 /

-2.85 (-3.53%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

GILD Gilead
$77.95 /

-2.85 (-3.53%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

GILD Gilead
$77.95 /

-2.85 (-3.53%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

GILD Gilead
$77.95 /

-2.85 (-3.53%)

Hot Stocks
Gilead signs remdesivir licensing deals with Mylan, four other manufacturers » 14:05
05/12/20
05/12
14:05
05/12/20
14:05
GILD

Gilead

$79.90 /

-0.9 (-1.11%)

, MYL

Mylan

$16.79 /

-0.125 (-0.74%)

Gilead (GILD) said it has…

Gilead (GILD) said it has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir. The agreements allow the companies - Cipla Ltd., Ferozsons Laboratories, Hetero Labs., Jubilant Lifesciences and Mylan (MYL) - to manufacture remdesivir for distribution in 127 countries. "The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access," Gilead said in a statement. Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding COVID-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, whichever is earlier. Reference Link

ShowHide Related Items >><<
MYL Mylan
$16.79 /

-0.125 (-0.74%)

GILD Gilead
$79.90 /

-0.9 (-1.11%)

GILD Gilead
$79.90 /

-0.9 (-1.11%)

05/11/20 RBC Capital
Gilead's U.S. remdesivir supply to be 'severely constrained', says RBC Capital
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Citi
ICER value of Remdesivir at $4,500 supportive of value, says Citi
05/04/20 Benchmark
Regeneron report more about COVID-19 progress than earnings, says Benchmark
MYL Mylan
$16.79 /

-0.125 (-0.74%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
MYL Mylan
$16.79 /

-0.125 (-0.74%)

GILD Gilead
$79.90 /

-0.9 (-1.11%)

MYL Mylan
$16.79 /

-0.125 (-0.74%)

GILD Gilead
$79.90 /

-0.9 (-1.11%)

MYL Mylan
$16.79 /

-0.125 (-0.74%)

GILD Gilead
$79.90 /

-0.9 (-1.11%)

MYL Mylan
$16.79 /

-0.125 (-0.74%)

GILD Gilead
$79.90 /

-0.9 (-1.11%)

Hot Stocks
Mylan says on track to close pending Upjohn combination in second half » 08:38
05/11/20
05/11
08:38
05/11/20
08:38
MYL

Mylan

$17.58 /

+0.22 (+1.27%)

Mylan CEO Heather Bresch…

Mylan CEO Heather Bresch said, "As we navigate the COVID-19 environment, our hearts and thoughts are with those who have been affected by COVID-19, and all of the healthcare workers and first responders who continue to go above and beyond to help save lives across the globe. I also would like to extend a special message of gratitude to our own Mylan family around the world. Thanks to their commitment, we have been able to continue meeting patient needs, even amid the challenges of a global pandemic. These efforts are reflected in our first quarter results, which came in with total revenues growing 5%, or 8% on a constant currency basis. We're also reaffirming revenue guidance to be in the range of $11.5B and $12.5B, absorbing approximately $200M of foreign exchange headwinds versus our previous expectations, and adjusted EBITDA to be in the range of $3.2B to $3.9B, absorbing approximately $50M of foreign exchange headwinds versus our previous expectations. These ranges account for COVID-19 impacts forecasted through the second quarter. Looking ahead, we remain on track to close the pending combination with Pfizer's Upjohn Business in the second half of the year and continue to have great confidence that Viatris will be well positioned to deliver value for all of our stakeholders as a true partner of choice."

ShowHide Related Items >><<
MYL Mylan
$17.58 /

+0.22 (+1.27%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
Earnings
Mylan reports Q1 revenue $2.62B, consensus $2.65B » 08:35
05/11/20
05/11
08:35
05/11/20
08:35
MYL

Mylan

$17.58 /

+0.22 (+1.27%)

Reports Q1 U.S. GAAP net…

Reports Q1 U.S. GAAP net earnings of $20.8M, compared to U.S. GAAP net loss of $(25.0M) in the prior year period. Reports Q1 adjusted net earnings of $467.2M, compared to adjusted net earnings of $421.9M in the prior year period. Mylan President Rajiv Malik said, "During these trying times, I am especially inspired by the dedication of Mylan's manufacturing colleagues who, with the support of their families, are continuing to work on-site to respond to the need for critical medicines. As a result of the Mylan team's efforts, our broad and diverse manufacturing footprint of more than 40 manufacturing facilities, which is spread across 12 countries, has maintained supply continuity. The strategic locations of our plants have enabled Mylan to avoid disruptions due to logistical challenges in any one part of the world. We have further mitigated risk by having multiple API and finished dose sources where possible, and we are continuously monitoring the inventory levels of our raw materials and the finished dosage form of our products. At this time, we do not foresee any supply disruptions, which we believe is a result of our geographic spread and supplier diversity." Mylan CFO Ken Parks added, "During the first quarter, we generated $357M of adjusted free cash flow, an increase of $330M over the prior year, primarily driven by working capital velocity and timing of certain other payments. As evidenced by our strong first quarter cash flow, we are pleased with our liquidity position despite the COVID-19 pandemic and anticipate full year adjusted free cash flow generation to be consistent with 2019 levels. We continue to target approximately $1B of debt repayment during 2020 and remain fully committed to our investment grade credit rating."

ShowHide Related Items >><<
MYL Mylan
$17.58 /

+0.22 (+1.27%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
Earnings
Mylan backs FY20 revenue view $11.5B-$12.5B, consensus $11.74B » 08:35
05/11/20
05/11
08:35
05/11/20
08:35
MYL

Mylan

$17.58 /

+0.22 (+1.27%)

Sees FY20 adjusted EBITDA…

Sees FY20 adjusted EBITDA $3.2B-$3.9B. This range accounts for COVID-19 impacts forecasted through Q2, and assumes healthcare systems around the world will begin to resume their normal functions in the second half of 2020.

ShowHide Related Items >><<
MYL Mylan
$17.58 /

+0.22 (+1.27%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.